TCM
ARQT icon

Teza Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Teza Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,327
Closed -$96K – 499
2024
Q3 		$96K Sell
10,327
-12,547
-55% -$124K 0.01% 572
2024
Q2 		$213K Buy
+22,874
New +$207K 0.03% 525

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Teza Capital Management's ARQT Position: Q4 2024 in Review

Teza Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q4 2024, closing a stake of 10,327 shares — an estimated $96K sold.

Teza Capital Management first reported a position in ARQT in Q2 2024 and held it in 2 quarters. The position peaked at $213K in Q2 2024. 208 funds tracked by Wall St. Rank hold ARQT as of Q4 2024.

  • Teza Capital Management reported no remaining Arcutis Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Teza Capital Management sold 10,327 Arcutis Biotherapeutics shares in Q4 2024, an estimated $96K.
  • Teza Capital Management first reported a position in Arcutis Biotherapeutics in Q2 2024 and held it in 2 quarters.
  • Teza Capital Management's Arcutis Biotherapeutics position peaked at $213K in Q2 2024.
  • 208 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2024.

Based on Teza Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.